{"filing":{"accession_number":"0001193125-26-298525","cik":"0001609809","ticker":"MCRB","company_name":"Seres Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"d100733d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526298525/d100733d8k.htm"},"events":[{"id":16681,"run_id":14911,"accession_number":"0001193125-26-298525","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Stockholders approved five proposals at the Annual Meeting held on July 8, 2026: election of three Class II directors (Stephen A. Berenson, Claire M. Fraser, and Richard N. Kender), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, approval of an amendment to the 2025 Incentive Award Plan increasing available shares by 900,000, and approval of an adjournment provision. All proposals passed.","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14851,"accession_number":"0001193125-26-298525","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the 2025 Incentive Award Plan increasing available shares by 900,000 shares. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves approval of a material equity plan amendment that affects the pool of shares available for executive and employee compensation grants. The materiality stems from the significant increase in authorized equity and its potential dilutive impact on shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:06:40.010670+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14852,"accession_number":"0001193125-26-298525","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder voting results from an Annual Meeting held on July 8, 2026. The filing reports the outcomes of five proposals: election of three Class II directors (Stephen A. Berenson, Claire M. Fraser, and Richard N. Kender), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, approval of an amendment to the 2025 Plan to increase share availability, and approval of an adjournment provision. All proposals passed. This is material as it confirms governance decisions and capital allocation authority (equity plan expansion).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:06:40.010670+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14851,"accession_number":"0001193125-26-298525","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the 2025 Incentive Award Plan increasing available shares by 900,000 shares. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves approval of a material equity plan amendment that affects the pool of shares available for executive and employee compensation grants. The materiality stems from the significant increase in authorized equity and its potential dilutive impact on shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:06:40.010670+00:00","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-07-08"},{"id":14852,"accession_number":"0001193125-26-298525","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder voting results from an Annual Meeting held on July 8, 2026. The filing reports the outcomes of five proposals: election of three Class II directors (Stephen A. Berenson, Claire M. Fraser, and Richard N. Kender), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, approval of an amendment to the 2025 Plan to increase share availability, and approval of an adjournment provision. All proposals passed. This is material as it confirms governance decisions and capital allocation authority (equity plan expansion).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:06:40.010670+00:00","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-07-08"}]}